Low free testosterone in HIV-infected men is not associated with subclinical cardiovascular disease

HIV Medicine

Volumn 13, Issue 6, 2012, Pages 358-366

  Monroe, A K ^a   Dobs, A S ^a   Xu, X ^a   Palella, F J ^b   Kingsley, L A ^c   Post, W S ^a   Witt, M D ^d   Brown, T T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; HIV; Testosterone

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTILIPEMIC AGENT; ATAZANAVIR; CALCIUM; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TESTOSTERONE; TIPRANAVIR; ZIDOVUDINE;

ADULT; ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; BODY MASS INDEX; CALCINOSIS; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; TESTOSTERONE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862786523     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00988.x     Document Type: Article

References (41)

1. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
2. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
3. Friis-Møller N, Sabin C, Weber R etal. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
4. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75.
5. Shores M, Matsumoto A, Sloan K, Kivlahan D. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-1665.
6. Selvin E, Feinleib M, Zhang L etal. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-238.
7. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226-234.
8. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol 2009; 161: 435-442.
9. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84: 611-616.
10. Wunder DM, Bersinger NA, Fux CA etal. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007; 12: 261-265.
11. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126: 310-318.
12. Kingsley L, Cuervo-Rojas J, Muñoz A etal. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: multicenter AIDS Cohort Study. AIDS 2008; 22: 1589-1599.
13. Kaplan R, Kingsley L, Gange S etal. Low CD4+ T cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22: 1615-1624.
14. Agatston A, Janowitz W, Hildner F, Zusmer N, Viamonte JM, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
15. Hodis H, Mack W, LaBree L, Selzer R, Liu C, Azen S. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-269.
16. Selzer R, Hodis H, Kwong-Fu H, Mack W, Lee P, Liu C. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 1994; 111: 1-11.
17. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672.
18. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Monroe AK, Dobs AS, Xu X etal. Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. J Acquir Immune Defic Syndr 2011; 58: 173-180.
20. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 1240-1244.
21. Bhasin S, Cunningham GR, Hayes FJ etal. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
22. Simon D, Charles M, Nahoul K etal. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82: 682-685.
23. Tajar A, Forti G, O'Neill TW etal. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95: 1810-1818.
24. Menke A, Guallar E, Rohrmann S etal. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010; 171: 583-592.
25. Khaw K, Dowsett M, Folkerd E etal. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701.
26. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97: 870-875.
27. Muller M, van den Beld A, Bots M, Grobbee D, Lamberts S, van der Schouw Y. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004; 109: 2074-2079.
28. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab 2006; 91: 4433-4437.
29. Hak A, Witteman J, de Jong F, Geerlings M, Hofman A, Pols H. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632-3639.
30. Michos E, Vaidya D, Gapstur S etal. Sex hormones, sex hormone binding globulin, and abdominal aortic calcification in women and men in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2008; 200: 432-438.
31. Mäkinen J, Järvisalo M, Pöllänen P etal. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005; 45: 1603-1608.
32. Muller M, van der Schouw YT, Thijssen JHH, Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 88: 5076-5086.
33. Friis-Møller N, Weber R, Reiss P etal. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
34. Riddler S, Smit E, Cole S etal. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-2982.
35. Brown TT, Cole SR, Li X etal. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-1184.
36. Bozzette S, Ake C, Tam H, Chang S, Louis T. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
37. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
38. Friis-Møller N, Reiss P, Sabin C etal. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
39. El-Sadr W, Lundgren J, Neaton J etal. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
40. Currier J, Kendall M, Zackin R etal. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19: 927-933.
41. Folsom AR, Kronmal RA, Detrano RC etal. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008; 168: 1333-1339.